Since then, Surfix has been on a mission to revolutionize point-of-care diagnostics through its innovative Photonic Diagnostic Platform: a multi-modal solution that delivers lab-level precision for protein detection, combined with the speed and ease of point-of-care testing (POCT).

The platform integrates advanced photonics and proprietary selective coating technologies with smart microfluidics to provide fast, highly accurate, and cost-effective diagnostics. It is particularly well-suited for detecting biomarkers at sensitivity levels beyond the reach of conventional POCTs—addressing a critical unmet need in healthcare. Potential applications range from infectious disease detection to chronic disease monitoring, aligning closely with the interests of major diagnostic players.

Progress has accelerated in Wageningen. Last year, two top-tier diagnostics companies conducted paid, blinded evaluations of Surfix’s platform. Both reported excellent results and initiated larger follow-up studies. This year, one of those companies confirmed Surfix’s exceptional sensitivity in blood plasma, achieving a detection limit of 1 picogram/mL for IL-6. The results were benchmarked against a state-of-the-art central lab system, validating the platform’s lab-grade precision in a POCT format. The other partner co-prepared a major IHI grant application with Surfix.

Meanwhile, Surfix continues to scale its operations, with a sharp focus on key value inflection points. The company also accepts co-development projects for immunoassays, generating early revenues and fostering partnerships with leading diagnostics companies.